Trial aims to Fine-Tune powerful cancer treatment for kids
NCT ID NCT07223021
Summary
This study is testing if adjusting the dose of a chemotherapy drug (fludarabine) based on a patient's individual metabolism improves the effectiveness of a subsequent CAR-T cell therapy for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia (B-ALL). Researchers will compare this personalized dosing approach to the standard fixed dose to see which one helps patients stay cancer-free longer. The goal is to make the preparatory step before CAR-T therapy more effective and potentially reduce the risk of the cancer coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Philadelphia (Data Collection Only)
NOT_YET_RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-••••
-
Cincinnati Children's Hospital Medical Center (Data Collection Only)
RECRUITINGCincinnati, Ohio, 45229, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.